Molecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease

Alzheimer Disease and Associated Disorders

Volumn 17, Issue 4, 2003, Pages 259-266

  Gandy, Sam ^a   Martins, Ralph N ^b   Buxbaum, Joseph ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b EDITH COWAN UNIVERSITY   (Australia)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTILIPEMIC AGENT; BETA SECRETASE; CURCUMIN; ENZYME INHIBITOR; ESTRADIOL; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE; PROTEIN ANTIBODY;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BLOOD BRAIN BARRIER; DEMENTIA; ENZYME ACTIVITY; HUMAN; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTIC ENDOPEPTIDASES; ENDOPEPTIDASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SENILE PLAQUES;

EID: 0347506014     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200310000-00011     Document Type: Review

References (72)

1. Glenner GC and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885-890.
2. Gandy S, Greengard P. Processing of A-beta-amyloid precursor protein: cell biology, regulation, and role in Alzheimer disease. Intl Rev Neurobiol. 1994;36:29-50.
3. Black RA, Rauch CT, Kozloskv CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729-733.
4. Buxbaum JD, Liu KN, Lulo Y, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem. 1998;273:27765-27767.
5. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281-1284.
6. Gouras GK, Xu H, Jovanovic JN, et al. Generation and regulation of beta-amyloid peptide variants by neurons. J Neurochem. 1998;71:1920-1925.
7. Sherrington R, Rogaev E, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-760.
8. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
9. Borchelt DR, Thinakaran GI, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate A-beta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005-1013.
10. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ 42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron 1994;12:45-53.
11. Lemere CA, Blusztajn JK, Yamaguchi H, et al. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 1996;3:16-32.
12. Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol. 2002;3:673-684.
13. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4:887-893.
14. Buxbaum JD, Gandy SE, Cicchetti P, et al. Processing of Alzheimer beta/ A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA. 1990;87:6003-6006.
15. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin I regulate processing and secretion of the Alzheimer beta A4 amyloid protein precursor. Proc Natl Acad Sci USA. 1992;89:10075-10078.
16. Buxbaum JD, Koo EH, Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloid/A4 peptide. Proc Natl Acad Sci USA. 1993;90:9195-9198.
17. Caporaso GL, Gandy SE, Buxbaum JD, et al. Protein phosphorylation regulates secretion of Alzheimer B/A4 amyloid precursor protein. Proc Natl Acad Sci USA. 1992;89:3055-3059.
18. Gillespie SL, Golde TE, Younkin SG. Secretory processing of the Alzheimer amyloid beta/A4 protein precursor is increased by protein phosphorylation. Biochem Biophys Res Commun. 1992;187:1285-1290.
19. Sinha S, Lieberburg I. Normal metabolism of the amyloid precursor protein (APP). Neurodegeneration. 1992;1:169-175.
20. Nitsch RM, Slack BF, Wurtman RJ, et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304-307.
21. Haring R, Fisher A, Marciano D, et al. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. J Neurochem. 1998;71:2094-2103.
22. Hung AY, Haass C, Nitsch PM, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta protein. J Biol Chem. 1993;268:22959-22962.
23. Savage MJ, Trusko SP, Howland DS, et al. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci. 1998;18:1743-1752.
24. Jaffe AB, Toran-Allerand CD, Greengard P, et al. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem. 1994;269:13065-13068.
25. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med. 1998;4:447-451.
26. Chang D, Kwan J, Timiras PS. Estrogens influence growth, maturation and amyloid beta-peptide production in neuroblastoma cells and in a beta-APP transfected kidney 293 cell line. Adv Exp Med Biol. 1997;429:261-271.
27. Danenboerg HD, Harin R, Heldman E, et al. Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12M1 cells. Ann NY Acad Sci. 1995;774:300-303.
28. Danenboerg HD, Haring R, Fisher A, et al. Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein. Life Sci. 1996;59:1651-1657.
29. Maeda T, Lloyd RV. Protein kinase C activity and messenger RNA modulation by estrogen in normal and neoplastic rat pituitary tissue. Lab Invest. 1993;68:472-480.
30. Maizels ET, Miller JB, Cutler RJ, et al. Estrogen modulates Ca2+-independent lipid-stimulated kinase in the rabbit corpus luteum of pseudopregnancy: identification of luteal estrogen-modulated lipid stimulated kinase as protein kinase C delta. J Biol Chem. 1992;267:17061-17068.
31. Karnel F, Kubajak CL. Gonadal steroid effects on LH response to arachadonic acid and protein kinase C. Am J Physiol 1988;155:314-321.
32. Drouva SV, Geronne I, Laplante E, et al. Estradiol modulates protein kinase C activity in the rat pituitary in vivo and in vitro. Endocrinology. 1990;126:536-544.
33. da Cruz e Silva O, Iverfeldt K, Oltersdorf T, et al. Regulated cleavage of Alzheimer beta-amyloid precursor protein in the absence of the cytoplasmic tail. Neuroscience. 1993;57:873-877.
34. Sahasrabudhe SR, Spruyt MA, Muenkel HA, et al. Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells. J Biol Chem. 1992;267:25062-25608.
35. Gandy S, Czernik AJ, Greengard P. Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca+2/calmodulin-dependent protein kinase II. Proc Natl Acad Sci USA. 1988;85:6218-6221.
36. Xu H, Greengard P, Gandy S. Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. J Biol Chem. 1995;270:21243-21245.
37. Caporaso GL, Takei K, Gandy S, et al. Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein. J Neurosci. 1994;14(5 Pt 2):3122-3138.
38. Bosenberg MW, Pandiella A, Massague J. Activated release of membrane-anchored TGF-alpha in the absence of cytosol. J Cell Biol. 1993;122:95-101.
39. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292:1550-1552.
40. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273:32730-32738.
41. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters central nervous system and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850-8855.
42. Cai H, Wang Y, McCarthy D, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233-234.
43. Wong PC, Zheng H, Chen H, et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997;387:288-292.
44. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709-5714.
45. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21:8370-8377.
46. in't Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.
47. Deleted in proof.
48. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic A-beta 42 independently of cyclo-oxygenase activity. Nature. 2001;414:212-216.
49. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
50. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-331.
51. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890-899.
52. Janus C, Pearson J, McLaurin J, et al. A-beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979-982.
53. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;22:38:547-554.
54. Gandy S, Greengard P. Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities. Trends Pharmacol Sci. 1992;13:108-113.
55. Petanceska SS, Nagy V, Frail D, et al. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Neurology. 2000;54:2212-2217.
56. Callahan MJ, Lipinski WJ, Bian F, et al. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol. 2001;158:1173-1177.
57. Zheng H, Xu H, Uljon SN, et al. Modulation of A-beta peptides by estrogen in mouse models. J Neurochem. 2002;80:191-196.
58. Tang MX, Jacobs D, Stem Y, et al. Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
59. Mayeux R, Gandy S. Cognitive impairment, Alzheimer's disease and other dementias. In: Goldman MB, Hatch MC, eds. Women and Health. San Diego: Academic Press, 2000.
60. Gandy SE, Almeida O, Fonte J, et al. Chemical andropause and amyloid-β peptide. JAMA 2001;285:2195-2196.
61. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663-2672.
62. Burdick D, Soreghan B, Kwon M, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/amyloid peptide analogs. J Biol Chem. 1992;267:546-554.
63. Pike CJ, Burdick D, Walencewicz AJ, et al. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993;13:1676-1687.
64. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone in patients with cerebral and systemic amyloid. Neurosci Lett. 1992;135:235-238.
65. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263-264.
66. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
67. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977-1981.
68. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993;11:575-580.
69. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta amyloid protein. N Engl J Med. 1995;333:1242-1247.
70. Yang DS, Small DH, Seydel U, et al. Apolipoprotein E promotes the association of amyloid-beta with Chinese Hamster Ovary cells in an isoform-specific manner. Neuroscience. 1999;90:1217-1226.
71. Holtzman DM, Fagan AM, Mackey B, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol. 2000;47:739-747.
72. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2000;97:2892-2897.